WallStreetZenWallStreetZen

NASDAQ: PMVP
Pmv Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their PMVP stock forecasts and price targets.

Forecast return on equity

Is PMVP forecast to generate an efficient return?

Company
-47.55%
Industry
281.79%
Market
232.3%
PMVP's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is PMVP forecast to generate an efficient return on assets?

Company
-42.98%
Industry
96.34%
PMVP is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

PMVP earnings per share forecast

What is PMVP's earnings per share in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
-$1.59
Avg 2 year Forecast
-$1.51
Avg 3 year Forecast
-$1.39

PMVP revenue forecast

What is PMVP's revenue in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$16.4M

PMVP vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
PMVP$1.38N/AN/A
ATYR$0.75$13.50+1,692.83%Buy
ALXO$1.38$1.00-27.54%Strong Buy
LITS$2.02N/AN/A
CRVO$7.68$22.80+196.88%Strong Buy
View Top Biotech Stocks

Pmv Pharmaceuticals Stock Forecast FAQ

What is PMVP's earnings growth forecast for 2025-2027?

(NASDAQ: PMVP) Pmv Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 48%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 43.33%.

Pmv Pharmaceuticals's earnings in 2025 is -$82,705,000.On average, 6 Wall Street analysts forecast PMVP's earnings for 2025 to be -$84,670,150, with the lowest PMVP earnings forecast at -$84,478,589, and the highest PMVP earnings forecast at -$86,043,007. On average, 6 Wall Street analysts forecast PMVP's earnings for 2026 to be -$80,461,120, with the lowest PMVP earnings forecast at -$87,607,425, and the highest PMVP earnings forecast at -$54,195,920.

In 2027, PMVP is forecast to generate -$74,086,381 in earnings, with the lowest earnings forecast at -$90,736,262 and the highest earnings forecast at -$55,313,362.

If you're new to stock investing, here's how to buy Pmv Pharmaceuticals stock.

What is PMVP's revenue growth forecast for 2025-2027?

(NASDAQ: PMVP) Pmv Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 104.93%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.7%.

Pmv Pharmaceuticals's revenue in 2025 is $0.On average, 6 Wall Street analysts forecast PMVP's revenue for 2025 to be $0, with the lowest PMVP revenue forecast at $0, and the highest PMVP revenue forecast at $0. On average, 5 Wall Street analysts forecast PMVP's revenue for 2026 to be $0, with the lowest PMVP revenue forecast at $0, and the highest PMVP revenue forecast at $0.

In 2027, PMVP is forecast to generate $873,573,310 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $1,798,548,937.

What is PMVP's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: PMVP) forecast ROA is -42.98%, which is lower than the forecast US Biotechnology industry average of 96.34%.

What is PMVP's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: PMVP) Pmv Pharmaceuticals's current Earnings Per Share (EPS) is -$1.60. On average, analysts forecast that PMVP's EPS will be -$1.59 for 2025, with the lowest EPS forecast at -$1.59, and the highest EPS forecast at -$1.62. On average, analysts forecast that PMVP's EPS will be -$1.51 for 2026, with the lowest EPS forecast at -$1.65, and the highest EPS forecast at -$1.02. In 2027, PMVP's EPS is forecast to hit -$1.39 (min: -$1.71, max: -$1.04).

What is PMVP's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: PMVP) forecast ROE is -47.55%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.